Cite
Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression
MLA
Wei Huang, et al. “Terfenadine Resensitizes Doxorubicin Activity in Drug-Resistant Ovarian Cancer Cells via an Inhibition of CaMKII/CREB1 Mediated ABCB1 Expression.” Frontiers in Oncology, vol. 12, Nov. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.1068443.
APA
Wei Huang, Shu Yang, Yu-Shan Cheng, Ni Sima, Wei Sun, Min Shen, John C. Braisted, Weiguo Lu, & Wei Zheng. (2022). Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1068443
Chicago
Wei Huang, Shu Yang, Yu-Shan Cheng, Ni Sima, Wei Sun, Min Shen, John C. Braisted, Weiguo Lu, and Wei Zheng. 2022. “Terfenadine Resensitizes Doxorubicin Activity in Drug-Resistant Ovarian Cancer Cells via an Inhibition of CaMKII/CREB1 Mediated ABCB1 Expression.” Frontiers in Oncology 12 (November). doi:10.3389/fonc.2022.1068443.